UBS AM
MGNX icon

UBS AM’s MacroGenics MGNX Stock Holding History

UBS AM’s Portfolio MGNX Stock Details MGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$159 Buy
+55
New +$117 ﹤0.01% 3782
2025
Q3 		– Sell
-219,000
Closed -$265K – 2470
2025
Q2 		$265K Buy
+219,000
New +$318K ﹤0.01% 2535
2024
Q3 		– Sell
-67,782
Closed -$288K – 2832
2024
Q2 		$288K Buy
67,782
+40,882
+152% +$398K ﹤0.01% 2726
2024
Q1 		$396K Buy
+26,900
New +$407K ﹤0.01% 2347
2022
Q4 		– Sell
-30,117
Closed -$104K – 2672
2022
Q3 		$104K Sell
30,117
-18,796
-38% -$71.9K ﹤0.01% 2683
2022
Q2 		$144K Hold
48,913
– – ﹤0.01% 2616
2022
Q1 		$431K Hold
48,913
– – ﹤0.01% 2507
2021
Q4 		$785K Hold
48,913
– – ﹤0.01% 2341
2021
Q3 		$1.02M Sell
48,913
-3,754
-7% -$90.4K ﹤0.01% 2153
2021
Q2 		$1.41M Sell
52,667
-475
-0.9% -$13.9K ﹤0.01% 2013
2021
Q1 		$1.69M Buy
53,142
+8,217
+18% +$200K ﹤0.01% 1826
2020
Q4 		$1.03M Hold
44,925
– – ﹤0.01% 1978
2020
Q3 		$1.13M Buy
44,925
+3,270
+8% +$89.3K ﹤0.01% 1789
2020
Q2 		$1.16M Sell
41,655
-600,094
-94% -$10.4M ﹤0.01% 1734
2020
Q1 		$3.73M Sell
641,749
-85,708
-12% -$778K ﹤0.01% 1162
2019
Q4 		$7.91M Buy
727,457
+11,997
+2% +$119K ﹤0.01% 1029
2019
Q3 		$9.13M Buy
715,460
+1,649
+0.2% +$23.7K 0.01% 983
2019
Q2 		$12.1M Buy
713,811
+245,313
+52% +$4.21M 0.01% 902
2019
Q1 		$8.42M Sell
468,498
-51,705
-10% -$894K 0.01% 975
2018
Q4 		$6.61M Buy
520,203
+41,087
+9% +$689K 0.01% 984
2018
Q3 		$10.3M Sell
479,116
-8,485
-2% -$181K 0.01% 932
2018
Q2 		$10.1M Buy
487,601
+142,160
+41% +$3.2M 0.01% 949
2018
Q1 		$8.69M Sell
345,441
-35,952
-9% -$873K 0.01% 970
2017
Q4 		$7.25M Buy
381,393
+10,249
+3% +$191K 0.01% 995
2017
Q3 		$6.86M Sell
371,144
-425
-0.1% -$7.36K 0.01% 994
2017
Q2 		$6.51M Sell
371,569
-27,699
-7% -$528K 0.01% 982
2017
Q1 		$7.43M Sell
399,268
-34,586
-8% -$667K 0.01% 953
2016
Q4 		$8.87M Sell
433,854
-91,817
-17% -$2.31M 0.01% 891
2016
Q3 		$15.7M Sell
525,671
-30,673
-6% -$912K 0.02% 763
2016
Q2 		$15M Sell
556,344
-117,836
-17% -$2.66M 0.02% 775
2016
Q1 		$12.6M Sell
674,180
-177,644
-21% -$3.38M 0.01% 790
2015
Q4 		$26.4M Buy
851,824
+34,477
+4% +$1.05M 0.03% 558
2015
Q3 		$17.5M Sell
817,347
-8,794
-1% -$276K 0.02% 717
2015
Q2 		$31.4M Buy
826,141
+6,032
+0.7% +$198K 0.03% 562
2015
Q1 		$25.7M Buy
820,109
+212,232
+35% +$7.19M 0.02% 628
2014
Q4 		$21.3M Buy
607,877
+171,127
+39% +$4.27M 0.02% 682
2014
Q3 		$9.13M Buy
436,750
+95,033
+28% +$1.97M 0.01% 865
2014
Q2 		$7.42M Sell
341,717
-38,984
-10% -$820K 0.01% 938
2014
Q1 		$10.6M Buy
380,701
+198,580
+109% +$7.01M 0.01% 831
2013
Q4 		$5M Buy
+182,121
New +$4.76M 0.01% 1010

Other funds holding MGNX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

UBS AM's MGNX Position: Q1 2026 in Review

UBS AM opened a new position in MacroGenics (MGNX) in Q1 2026: 55 shares worth $159. The stake represents ﹤0.01% of the portfolio and ranks #3782 among its holdings. This is a return to the name: UBS AM previously reported a position in MGNX as recently as Q2 2025.

UBS AM first reported a position in MGNX in Q4 2013 and has held it in 40 quarters since. The position peaked at $31.4M in Q2 2015. 109 funds tracked by Wall St. Rank hold MGNX as of Q1 2026.

  • UBS AM held 55 shares of MacroGenics worth $159 as of Q1 2026.
  • MacroGenics was a new UBS AM position in Q1 2026.
  • MacroGenics made up ﹤0.01% of UBS AM's portfolio in Q1 2026, its #3782 holding.
  • UBS AM first reported a position in MacroGenics in Q4 2013 and has held it in 40 quarters since.
  • UBS AM's MacroGenics position peaked at $31.4M in Q2 2015.
  • 109 funds tracked by Wall St. Rank held MacroGenics as of Q1 2026.

Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.